Abstract
During routine surveillance, the US Food and Drug Administration (FDA) Division of Pharmacovigilance identified postmarketing cases of Stevens-Johnson Syndrome (SJS) and toxic epidermal necrolysis (TEN) associated with enfortumab vedotin (EV) from the FDA Adverse Event Reporting System (FAERS). To investigate a potential association between EV and SJS/TEN, we evaluated all sources for postmarketing cases of SJS/TEN and report our findings.